| 吕兰.血脂康联合非诺贝特治疗2型糖尿病合并高血脂症的临床疗效及安全性评价[J].浙江中西医结合杂志,2015,25(6): |
| 血脂康联合非诺贝特治疗2型糖尿病合并高血脂症的临床疗效及安全性评价 |
| Evaluate the clinical efficacy and safety of Xuezhikang and fenofibrate in treatment of type 2 diabetes with hyperlipidemia.evaluation |
| 投稿时间：2014-10-10 修订日期：2015-01-16 |
| DOI： |
| 中文关键词: 血脂康 非诺贝特 瑞舒伐他汀 2型糖尿病 高血脂 |
| 英文关键词:Xuezhikang fenofibrate rosuvastatin type 2 diabetes high blood lipids |
| 基金项目: |
|
| 摘要点击次数: 709 |
| 全文下载次数: 0 |
| 中文摘要: |
| 【】 目的 评价血脂康联合非诺贝特治疗2型糖尿病合并高血脂症的临床疗效及安全性。 方法 将80例高脂血症患者随机分为两组,其中对照组40例,每晚给予瑞舒伐他汀钙片10mg口服, qd；治疗组40例,给予血脂康0.6g,bid,早晚饭后服用,在此基础上给予非诺贝特胶囊(II)200 mg,qd,每天早晨与餐同服,疗程8周。观察两组患者在治疗前后血脂和血糖等指标的变化情况。 结果 治疗8周后,两组患者的血脂水平与治疗前相比均有明显改善,其中TC、TG和LDL-C较治疗前显著降低,而HDL-C较治疗前明显升高(P < 0.01)；治疗组在TC和TG的降幅上要优于对照组,而对照组在LDL-C的降幅上大于治疗组,差异有统计学意义(P < 0.05)。在血糖控制方面,治疗组能降低患者FPG和2hPG的水平(P < 0.05),尤其是显著降低患者的HbA1c水平(P < 0.01)；而对照组患者的治疗前后血糖基本没有影响(P > 0.05)。 结论 血脂康联合非诺贝特治疗2型糖尿病合并高血脂症能显著改善患者的血脂和血糖水平,同时安全性好,值得临床推广。 |
| 英文摘要: |
| Objective To evaluate the clinical efficacy and safety of Xuezhikang and fenofibrate in treatment of type 2 diabetes with hyperlipidemia. Methods 80 patients with hyperlipidemia were randomly divided into two groups, 40 patients in control group, every night to give Rosuvastatin Calcium Tablets oral 10mg, qd; 40 cases in the treatment group were treated by Xuezhikang, 0.6g, bid, sooner or later after meals, treated on the basis of Fenofibrate Capsules (II) 200 mg,qd, every morning and meals, 8 weeks. Two groups were observed in patients with changes in lipid and glucose and other indicators before and after the treatment situation. Results After 8 weeks of treatment, blood lipid level and treatment of two groups of patients were significantly improved compared to before, in which TC, TG and LDL-C were significantly lower after treatment than before, while HDL-C significantly after treatment (P < 0.01); the treatment group in the TC and TG drop is superior to the control group, while the control group were higher than the treatment group the decline in LDL-C, the difference was statistically significant (P < 0.05). In the control of blood sugar, the treatment group can reduce the FPG patients and 2hPG level (P < 0.05), especially in patients with HbA1c levels decreased significantly (P < 0.01); While the control groups of patients before and after therapy did not affect the basic blood sugar (P > 0.05). Conclusion Xuezhikang combined with fenofibrate in treatment of type 2 diabetes mellitus with hyperlipidemia can significantly improve the blood lipid and blood glucose level in patients, at the same time, the security is good, worthy of clinical application. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
